Neuroscience biotech led by former Pfizer crew wins $17M to target toxic tau

With big pharma players marching out of the disaster-prone field of neurosciences one-by-one, small biotechs are picking up the tab.

Cambridge, Massachusetts-based Pinteon Therapeutics is the latest initiative. The company, founded in 2014, is developing a tau antibody to address an array of neurodegenerative disorders. On Thursday, it unveiled $17 million in series A funding from Morningside Ventures.